ENTX Stock Analysis: Buy, Sell, or Hold?
ENTX - Entera Bio Ltd. Ordinary Shares
$1.16
-0.01 (-0.85%)
▼
5d:
-4.92%
30d:
-7.2%
90d:
-12.12%
BUY
HIGH Confidence
Analysis Updated: Jun 11, 2026 12:00 AM ET
Earnings: May 08, 2026
0d
Get Alerted When ENTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ENTX shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: ENTX shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
In-depth Analysis How we analyze
Valuation Analysis: ENTX is currently trading at $1.16, which is considered oversold relative to its 30-day fair value range of $1.18 to $1.29.
Technical Outlook: Technically, ENTX is in a downtrend. The price is currently testing key support at $1.16. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (1th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $9.00 (+675.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ENTX is in a downtrend. The price is currently testing key support at $1.16. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (1th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $9.00 (+675.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.18 -
$1.29
Company Quality Score
52/100
(HOLD)
Options IV Signal
1th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
86.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 1th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 675.9% below Wall St target ($9.00)
Trading Range Analysis
30-Day Trading Range
$1.18 -
$1.29
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.27
(23.0%)
Support & Resistance Levels
Support Level
$1.16
Resistance Level
$1.37
Current Trend
Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.04
Wall Street Target
$9.00
(+675.9%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: June 12, 2026 3:31 AM ET
Data refreshes hourly during market hours. Next update: 4:31 AM
Data refreshes hourly during market hours. Next update: 4:31 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ENTX showing a specific setup today?
Insider Activity (6 Months)
5
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Geno J Germano
BUY
20000 shares
2026-03-09
Sean Ellis
BUY
10000 shares
2026-03-05
Sean Ellis
BUY
18000 shares
2026-02-09
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 59 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$101 | 58 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 58 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 54 HOLD |
